| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 12th June 2019 | Allan L Goldstein | 228,000 | Bona fide gift | $0.00 | |
| 6th January 2019 | Allan L Goldstein | 208,912 | Conversion of derivative | $0.06 | $12,534.72 |
| 6th January 2019 | Joseph C Mcnay | 522,280 | Conversion of derivative | $0.06 | $31,336.80 |
Regene Rx Biopharmaceuticals
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
RegeneRx Biopharmaceuticals, Inc. focuses on the development of a novel therapeutic peptide, Thymosin beta 4, or Tß4. The company was founded by Allan L. Goldstein on May 13, 1982 and is headquartered in Rockville, MD.
Ticker: RGRX
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 707511
Employees: 4
Exchange: US OTC
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
We weren't able to import Fundamental data from the SEC disclosure.
There were no Red Flags found
Fundamentals
We weren't able to import Fundamental data from the SEC disclosure.
News
DXP Enterprises Reports Third Quarter 2020 Results
6th November 2020
17 Arrested For Running Fake Call Centre In Delhi: Police
6th November 2020
Ubiquiti Inc. Reports First Quarter Fiscal 2021 Financial Results
6th November 2020
